rs552422789

Variant summary

Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PP3PP4PS4_SupportingPM5PM2

This summary comes from the ClinGen Evidence Repository: NM_000527.5(LDLR):c.1217G>A (p.Arg406Gln) variant is classified as Likely pathogenic for Familial Hypercholesterolemia by applying evidence codes (PM2, PM5, PP3, PP4, PS4_Supporting) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PM2 - PopMax MAF = 0.00006164 (0.006%) in African/African American (gnomAD v2.1.1). PM5 - Two other missense variants described in the same codon (accessed 19 August 2020): --- 1 variant classified as Pathogenic by these guidelines.PP3 - REVEL: 0,809. PP4 - Variant meets PM2. Variant identified in 2 index cases fulfilling Simon-Broome criteria.PS4_supporting - Variant meets PM2. Variant identified in 2 index cases (PMID:10882754 - 1 case with Simon-Broome criteria; PMID:17094996 - 1 case with Simon-Broome criteria). LINK:https://erepo.genome.network/evrepo/ui/classification/CA033088/MONDO:0007750/013

Frequency

Genomes: đť‘“ 0.000013 ( 0 hom., cov: 29)
Exomes đť‘“: 0.0000068 ( 0 hom. )

Consequence

LDLR
NM_000527.5 missense

Scores

8
7
4

Clinical Significance

Likely pathogenic reviewed by expert panel P:12U:4

Conservation

PhyloP100: 4.32
Variant links:
Genes affected
LDLR (HGNC:6547): (low density lipoprotein receptor) The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. The encoded protein is normally bound at the cell membrane, where it binds low density lipoprotein/cholesterol and is taken into the cell. Lysosomes release the cholesterol, which is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2022]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_pathogenic. Variant got 7 ACMG points.

PS4
For more information check the summary or visit ClinGen Evidence Repository.
PM2
For more information check the summary or visit ClinGen Evidence Repository.
PM5
For more information check the summary or visit ClinGen Evidence Repository.
PP3
For more information check the summary or visit ClinGen Evidence Repository.
PP4
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
LDLRNM_000527.5 linkc.1217G>A p.Arg406Gln missense_variant 9/18 ENST00000558518.6 NP_000518.1 P01130-1A0A024R7D5

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
LDLRENST00000558518.6 linkc.1217G>A p.Arg406Gln missense_variant 9/181 NM_000527.5 ENSP00000454071.1 P01130-1

Frequencies

GnomAD3 genomes
AF:
0.0000132
AC:
2
AN:
151998
Hom.:
0
Cov.:
29
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000159
AC:
4
AN:
251042
Hom.:
0
AF XY:
0.0000221
AC XY:
3
AN XY:
135820
show subpopulations
Gnomad AFR exome
AF:
0.0000616
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000544
Gnomad SAS exome
AF:
0.0000327
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000882
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000684
AC:
10
AN:
1461320
Hom.:
0
Cov.:
33
AF XY:
0.00000688
AC XY:
5
AN XY:
726958
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000504
Gnomad4 SAS exome
AF:
0.0000116
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000450
Gnomad4 OTH exome
AF:
0.0000331
GnomAD4 genome
AF:
0.0000131
AC:
2
AN:
152116
Hom.:
0
Cov.:
29
AF XY:
0.0000134
AC XY:
1
AN XY:
74368
show subpopulations
Gnomad4 AFR
AF:
0.0000482
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000754
Hom.:
0
ExAC
AF:
0.0000165
AC:
2
Asia WGS
AF:
0.000289
AC:
1
AN:
3478

ClinVar

Significance: Likely pathogenic
Submissions summary: Pathogenic:12Uncertain:4
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Hypercholesterolemia, familial, 1 Pathogenic:7Uncertain:3
Likely pathogenic, reviewed by expert panelcurationClinGen Familial Hypercholesterolemia Variant Curation Expert PanelJun 09, 2021NM_000527.5(LDLR):c.1217G>A (p.Arg406Gln) variant is classified as Likely pathogenic for Familial Hypercholesterolemia by applying evidence codes (PM2, PM5, PP3, PP4, PS4_Supporting) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PM2 - PopMax MAF = 0.00006164 (0.006%) in African/African American (gnomAD v2.1.1). PM5 - Two other missense variants described in the same codon (accessed 19 August 2020): --- 1 variant classified as Pathogenic by these guidelines. PP3 - REVEL: 0,809. PP4 - Variant meets PM2. Variant identified in 2 index cases fulfilling Simon-Broome criteria. PS4_supporting - Variant meets PM2. Variant identified in 2 index cases (PMID: 10882754 - 1 case with Simon-Broome criteria; PMID: 17094996 - 1 case with Simon-Broome criteria). -
Likely pathogenic, criteria provided, single submitterclinical testingJuno Genomics, Hangzhou Juno Genomics, Inc-PM2_Supporting+PM5+PP3_Moderate+PS4_Moderate -
Uncertain significance, criteria provided, single submitterresearchFundacion Hipercolesterolemia FamiliarMar 01, 2016- -
Pathogenic, criteria provided, single submitterclinical testingU4M - Lille University & CHRU Lille, Université de Lille - CHRU de LilleMar 30, 2017- -
Pathogenic, no assertion criteria providedresearchLaboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, Academisch Medisch Centrum-- -
Uncertain significance, criteria provided, single submitterclinical testingCentre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies, APHP, GH Hôpitaux Universitaires Pitié-Salpêtrière / Charles-FoixDec 16, 2016subject mutated among 2600 FH index cases screened = 1 , family members = 3 with unclear co-segregation / Software predictions: Damaging -
Likely pathogenic, criteria provided, single submitterclinical testingAll of Us Research Program, National Institutes of HealthSep 25, 2024This missense variant replaces arginine with glutamine at codon 406 in LDLR type B repeat 1 in EGF precursor homology domain of the LDLR protein. This variant is also known as p.Arg385Gln in the mature protein. Computational prediction suggests that this variant may have a deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may create a new acceptor site. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in nine unrelated individuals affected with familial hypercholesterolemia (PMID: 10882754, 17094996, 23680767, 28008010, 29353225, 33418990, 34037665, 36499307, ClinVar SCV000503318.1). Different missense variants affecting the same codon, p.Arg406Trp and p.Arg406Pro, are considered to be disease-causing (ClinVar variation ID: 226351 and 226352), suggesting that arginine at this position is important for LDLR protein function. This variant has been identified in 4/251042 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. -
Likely pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityDec 07, 2022- -
Uncertain significance, criteria provided, single submittercurationBroad Center for Mendelian Genomics, Broad Institute of MIT and HarvardJan 22, 2020The p.Arg406Gln variant in LDLR has been reported in at least 9 individuals (including 1 African individual) with Familial Hypercholesterolemia (PMID: 17094996, 10882754, 23680767, 28008010; Variation ID: 228798), and has been identified in 0.001593% (4/251042) of chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs552422789). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported as a VUS, likely pathogenic variant, and pathogenic variant in ClinVar (Variation ID: 228798). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Two additional variants with a different amino acid change at the same position, p.Arg406Pro and p.Arg406Trp, have been reported in association with disease in ClinVar, supporting that a change at this position may not be tolerated (Variation ID: 226352, 226351). cDNA analysis of an individual with a synonymous variant in the same codon suggests that this region may be important for splicing (PMID: 18400033). In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM5, PS4_supporting, PP3 (Richards 2015). -
Likely pathogenic, criteria provided, single submitterliterature onlyLDLR-LOVD, British Heart FoundationMar 25, 2016- -
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitterclinical testingGeneDxMar 02, 2023Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; In silico analysis supports that this missense variant has a deleterious effect on splicing; Also known as R385Q; This variant is associated with the following publications: (PMID: 29353225, 34037665, 17094996, 28008010, 16466730, 33418990, 36499307, 10882754) -
Likely pathogenic, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoSep 18, 2024The LDLR c.1217G>A (p.Arg406Gln) variant has been reported in the published literature in individuals affected with Familial hypercholesterolemia, with the prevalence in FH patients being increased compared with the prevalence in controls (PMIDs: 33418990 (2021), 29353225 (2018), 17094996 (2007), 10882754 (2000)). The frequency of this variant in the general population, 0.000016 (4/251042 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is consistent with pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, this variant is classified as likely pathogenic. -
Familial hypercholesterolemia Pathogenic:2
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 16, 2024This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 406 of the LDLR protein (p.Arg406Gln). This variant is present in population databases (rs552422789, gnomAD 0.007%). This missense change has been observed in individuals with LDLR-related conditions (PMID: 10882754, 17094996, 28008010). ClinVar contains an entry for this variant (Variation ID: 228798). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LDLR protein function with a positive predictive value of 95%. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. This variant disrupts the p.Arg406 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8882879, 25461735, 26343872). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
Likely pathogenic, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthSep 26, 2023This missense variant replaces arginine with glutamine at codon 406 in LDLR type B repeat 1 in EGF precursor homology domain of the LDLR protein. This variant is also known as p.Arg385Gln in the mature protein. Computational prediction suggests that this variant may have a deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may create a new acceptor site. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in nine unrelated individuals affected with familial hypercholesterolemia (PMID: 10882754, 17094996, 23680767, 28008010, 29353225, 33418990, 34037665, 36499307, ClinVar SCV000503318.1). Different missense variants affecting the same codon, p.Arg406Trp and p.Arg406Pro, are considered to be disease-causing (ClinVar variation ID: 226351 and 226352), suggesting that arginine at this position is important for LDLR protein function. This variant has been identified in 4/251042 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. -
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsJul 29, 2024The p.R406Q variant (also known as c.1217G>A), located in coding exon 9 of the LDLR gene, results from a G to A substitution at nucleotide position 1217. The arginine at codon 406 is replaced by glutamine, an amino acid with highly similar properties. This alteration, which is also known as p.R385Q, has been reported in individuals with familial hypercholesterolemia (FH), including in an individual with concerns for homozygous FH, who had an additional alteration in LDLR identified (Thiart R et al. J Med Genet, 2000 Jul;37:514-9; Durst R et al. Atherosclerosis, 2006 Dec;189:443-50; Tosi I et al. Atherosclerosis, 2007 Sep;194:102-11; Abul-Husn NS et al. Science, 2016 Dec;354:[ePub ahead of print]; Pek SLT et al. Atherosclerosis, 2018 Feb;269:106-116; Razman AZ et al. Int J Mol Sci, 2022 Nov;23:[ePub ahead of print]; Ambry internal data). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
not specified Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingLaboratory for Molecular Medicine, Mass General Brigham Personalized MedicineApr 18, 2019Variant classified as Uncertain Significance - Favor Pathogenic. The p.Arg406Gln variant in LDLR has been reported in 4 individuals with hypercholesterolemia (Thiart 2000, Tosi 2007, Abul Husn 2016, Pek 2017). It has also been identified in 0.006% (1/16224) of African chromosomes by gnomAD (http://gnomad.broadinstitute.org) and is reported in ClinVar (Variation ID: 228798). Computational prediction tools and conservation analysis suggest that the p.Arg406Gln variant may impact the protein. In addition, splicing prediction tools predict this variant results in the generation of a novel 3' splice site. However, the results of these computational tools are not predictive enough to determine pathogenicity. An additional variant involving this codon (p.Arg406Trp) has been identified in individuals with hypercholesterolemia and is classified as pathogenic by this laboratory, suggesting variation at this site may not be tolerated. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM5, PM2_Supporting, PP3, PS4_Supporting. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.25
BayesDel_addAF
Uncertain
0.16
D
BayesDel_noAF
Pathogenic
0.17
CADD
Pathogenic
35
DANN
Pathogenic
1.0
DEOGEN2
Pathogenic
0.84
D;.;.;.;.;.
Eigen
Uncertain
0.60
Eigen_PC
Uncertain
0.48
FATHMM_MKL
Uncertain
0.96
D
LIST_S2
Pathogenic
0.98
D;D;D;D;D;D
M_CAP
Pathogenic
0.70
D
MetaRNN
Pathogenic
0.95
D;D;D;D;D;D
MetaSVM
Pathogenic
0.94
D
MutationAssessor
Benign
1.6
L;.;.;.;.;L
PrimateAI
Benign
0.37
T
PROVEAN
Uncertain
-3.5
D;D;D;D;D;D
REVEL
Pathogenic
0.81
Sift
Uncertain
0.023
D;D;D;D;D;D
Sift4G
Uncertain
0.021
D;D;D;D;D;D
Polyphen
1.0
D;.;.;.;.;.
Vest4
0.27
MutPred
0.95
Gain of ubiquitination at K411 (P = 0.0975);Gain of ubiquitination at K411 (P = 0.0975);.;.;.;Gain of ubiquitination at K411 (P = 0.0975);
MVP
1.0
MPC
0.56
ClinPred
0.81
D
GERP RS
4.9
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.62
gMVP
0.97

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.83
Details are displayed if max score is > 0.2
DS_AG_spliceai
0.83
Position offset: 2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs552422789; hg19: chr19-11223984; API